U.S. markets closed

Real Brands, Inc. (RLBD)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0570-0.0030 (-5.00%)
At close: 3:58PM EST
Sign in to post a message.
  • W
    William Waylett
  • p
    Does this stock still exist?
  • M
    Take a look At ERBB it’s starting to move .
  • Y
    what's going on? there was alot of volume yesterday
  • j
    $RLBD conversation
    $RLBD News!
    FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- Real Brands, Inc. (OTC: RLBD), today is announcing that we have signed a Letter of Intent with Wonder Labs, LLC to create a joint venture to leverage Real Brands brand building and sales capabilities with Wonder Labs product development and production capabilities. The joint venture will focus on accelerating development of innovative hemp derived CBD and other unique high-value consumer products and launching these products online and through traditional retail channels.

    “As we prepare to launch our HempAid®, Humboldt Brands®, Omegahemp™ and CBD Pharmacy™ brands, we have identified areas where we might benefit from additional resources,” said Real Brands, CEO Jerry Pearring. “By combining certain of Real Brands resources with Wonder Labs, we expect both parties will benefit from the other parties’ distinct strengths while creating a joint venture that is broader in scope than either company individually,” said Pearring.

    “As the hemp derived CBD consumer products marketplace evolves, new product innovation and speed to market are becoming increasingly important,” commented Wonder Labs CEO Vicky Arbelaez-Scoates. “We believe this joint venture not only enhances our efforts in these areas, but it also favorably impacts multiple other aspects of our existing operations as well.”

    Real Brands will have a controlling interest in the joint venture while assuming and performing all management and operational functions of the joint venture. In addition, Wonder Labs will initially contribute a new consumer product brand with innovative formulas while overseeing production of all products developed and launched by the joint venture through its affiliated owned and operated GMP and FDA certified manufacturing facility.

    About Real Brands

    Real Brands, Inc. (OTC: RLBD) is a publicly held company. Real Brands' vision is to be recognized as a leading brand building company in the legal Hemp-Derived CBD consumer products category. Real Brands plans to create a unique marketing strategy for each of its brands: CBD Pharmacy™, Omegahemp™, Humboldt Brands®, Hemp-Aid® and HempAid®. Real Brands aims to grow and expand by focusing on CBD Categories including ingestible and topical skin care products.

    For additional information go to www.realbrandsusa.com.
  • M
    NaturalShrimp Incorporated
    dig into ACRX 700% percent upside based on the 11/18 updated Seeking Alpha editor's valuation of AcelRx (ACRX), ACRX's DSUVIA was FDA approved on November 2nd, and ACRX's DSUVIA was EU approved 120 days ago; ACRX is also getting ready to file an NDA for their drug Zalviso. Heads up: $TWTR $VZ $RAZFF $PZOO $MYMX $RLBD $ISOLF $WEED $POTN $AXIM $APH $INNV $WTER $PTX $USMJ $ACB $KO $CBDS $GTX $IMLFF $KALY $TRUL $T
  • P
    I have emailed $RLBD 5 times asking for an update on:
    1) omega hemp water production run
    2) humbolt production
    3) CBD pharmacy sales
    4) audit update
    5) follow up to any news release in the last 9 months.
    All I hear is crickets!!!
    This is not a good way to run a company!!!
  • A
    $HEMP conversation
    $RLBD way better than HEMP
  • A
    $MCOA conversation
    $RLBD tiny CBD at $0.07 looking to breakout anytime
  • A
    $AAPL conversation
    $RLBD on watch, play gaining attention
  • M
    $RLBD conversation
    Did anyone else see $RLBD report from http://jcharlesassets.com/opiant-pharmaceuticals/?s=RLBD ? It had some interesting information. Day trading trading stocks. "hhse"
    Best MicroCap, Small Cap and Emerging Stocks to Buy - J Charles Assets
    We search for the smart new growing companies to invest in with stock deals to watch in pharmacuetical and digital verticals.